Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its lead product is Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion. The company is also developing NNZ-2591, a synthetic analogue of a naturally occurring neuropeptide that is in preclinical development for the treatment of various neurodegenerative disorders. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.
neuren pharmaceuticals ltd
(NEU:Australian Stock Exchange Ltd)
697 Burke Road
Camberwell, VIC 3124
Phone: 61 3 9092 0480
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for NEU.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact NEUREN PHARMACEUTICALS LTD, please visit www.neurenpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.